Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director | July 01, 2021 | July 02, 2021 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | November 05, 2025 | November 07, 2025 |
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director | June 15, 2017 | June 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENOCEA BIOSCIENCES, INC.
Report date July 01, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2031-07-01 | Direct | 15,000 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the options are scheduled to vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.
MADRIGAL PHARMACEUTICALS, INC.
Report date November 05, 2025 · Filed November 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,627 |
Ending reported balance
After 2025-11-05 transaction · row 14
14 source rows · reconciled sequenceRow 1 · 2025-11-05 · Exercise / conversion · Acquired 5,470 · Balance 8,097 Row 2 · 2025-11-05 · Exercise / conversion · Acquired 10,000 · Balance 18,097 Row 3 · 2025-11-05 · Exercise / conversion · Acquired 1,105 · Balance 19,202 Row 4 · 2025-11-05 · Sale · Disposed 1,763 · Balance 17,439 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.66 to $480.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 5 · 2025-11-05 · Sale · Disposed 3,259 · Balance 14,180 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.71 to $481.68, inclusive. Row 6 · 2025-11-05 · Sale · Disposed 1,284 · Balance 12,896 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.84 to $482.71, inclusive. Row 7 · 2025-11-05 · Sale · Disposed 2,069 · Balance 10,827 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.00 to $483.92, inclusive. Row 8 · 2025-11-05 · Sale · Disposed 1,931 · Balance 8,896 F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.02 to $485.015, inclusive. Row 9 · 2025-11-05 · Sale · Disposed 1,008 · Balance 7,888 F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.10 to $486.04, inclusive. Row 10 · 2025-11-05 · Sale · Disposed 827 · Balance 7,061 F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.10 to $486.99, inclusive. Row 11 · 2025-11-05 · Sale · Disposed 2,775 · Balance 4,286 F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.13 to $488.09, inclusive. Row 12 · 2025-11-05 · Sale · Disposed 696 · Balance 3,590 F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.74 to $489.49, inclusive. Row 13 · 2025-11-05 · Sale · Disposed 933 · Balance 2,657 F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.74 to $490.7125, inclusive. Row 14 · 2025-11-05 · Sale · Disposed 30 · Balance 2,627 F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $490.7625 to $491.42, inclusive. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.45 · Expires 2026-07-22 | Direct | 0 |
Reported balance
After 2025-11-05 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-11-05 · Exercise / conversion · Disposed 5,470 · Balance 0 F12: The shares underlying this option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $303.79 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2025-11-05 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-11-05 · Exercise / conversion · Disposed 10,000 · Balance 0 F12: The shares underlying this option are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $280.04 · Expires 2031-06-25 | Direct | 0 |
Reported balance
After 2025-11-05 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2025-11-05 · Exercise / conversion · Disposed 1,105 · Balance 0 F12: The shares underlying this option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.66 to $480.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.71 to $481.68, inclusive.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.84 to $482.71, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.00 to $483.92, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.02 to $485.015, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.10 to $486.04, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.10 to $486.99, inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.13 to $488.09, inclusive.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.74 to $489.49, inclusive.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.74 to $490.7125, inclusive.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $490.7625 to $491.42, inclusive.
F12: The shares underlying this option are fully vested and exercisable.
Vanda Pharmaceuticals Inc.
Report date June 15, 2017 · Filed June 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,000 |
Reported balance
After 2017-06-15 transaction · row 1
1 source rowRow 1 · 2017-06-15 · Grant · Acquired 5,000 · Balance 5,000 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.75 · Expires 2027-06-14 | Direct | 10,000 |
Reported balance
After 2017-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-15 · Grant · Acquired 10,000 · Balance 10,000 F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
F2: This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEO PHARMACEUTICALS, INC.
Report date January 19, 2023 · Filed January 19, 2023
Section 16 reporting ended · disclosed 2023-01-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 375 |
Reported balance
After 2023-01-19 transaction · row 1
1 source rowRow 1 · 2023-01-19 · Disposition to issuer · Disposed 375 · Balance 375 F1: Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.90 · Expires 2023-05-29 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-19 · Disposition to issuer · Disposed 1,250 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2024-06-19 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-19 · Disposition to issuer · Disposed 1,250 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.10 · Expires 2025-04-02 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-19 · Disposition to issuer · Disposed 2,515 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2025-05-28 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-01-19 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 · Expires 2026-05-26 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-01-19 · Disposition to issuer · Disposed 6,402 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-01-19 · Disposition to issuer · Disposed 7,785 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.70 · Expires 2028-06-17 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-01-19 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-01-19 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.52 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-01-19 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2031-06-08 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-01-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2032-06-06 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-01-19 · Disposition to issuer · Disposed 22,500 · Balance 0 F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.
F2: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Astria Therapeutics, Inc.
Report date January 23, 2026 · Filed January 23, 2026
Section 16 reporting ended · disclosed 2026-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Disposition to issuer · Disposed 16,666 · Balance 0 F1: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-23 · Disposition to issuer · Disposed 8,333 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.35 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-23 · Disposition to issuer · Disposed 14,100 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.18 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-23 · Disposition to issuer · Disposed 14,100 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.79 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-23 · Disposition to issuer · Disposed 26,550 · Balance 0 F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
F2: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Epizyme, Inc.
Report date August 12, 2022 · Filed August 16, 2022
Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-12 · Disposition to issuer · Disposed 8,060 · Balance 8,994 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 8,994 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.
F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2021 Filed Jun 15, 2021 16:41 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 40,559 | $0.00 Strike: $8.53 | $0.00 |
DisclosureSEC source: 0000899243-21-023878 · doc4.xml · derivative · entry 2 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,559 Underlying: Common Stock · 40,559 shares Expires 2031-06-10 F2 · derivative.exercise_date: This option was granted on June 11, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:41 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 8,060 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-023878 · doc4.xml · nonDerivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,060 F1 · shares: Consists of shares of Common Stock issuable under 8,060 restricted stock units ("RSUs") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document |
| June 09, 2021 Filed Jun 9, 2021 17:17 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0000899243-21-022796 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments beginning July 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 19:16 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-21-075905 · tm2118270-6_4seq1.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: This option was granted on June 2, 2021 and is schedule to vest in equal annual installments over a three-year period from the date of grant, subject to the director's continued service. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 16:12 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001457612-20-000102 · wf-form4_159259751850100.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 11:46 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $111.06 | $0.00 |
DisclosureSEC source: 0000899243-20-016988 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-06-17 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 11:44 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001104659-20-072733 · a4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest in full on June 11, 2021. Read SEC document |
| June 10, 2020 Filed Jun 30, 2020 16:34 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0000899243-20-017970 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from July 1, 2020 through June 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:15 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 14,013 | $0.00 Strike: $17.55 | $0.00 |
DisclosureSEC source: 0000899243-20-014895 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,013 Underlying: Common Stock · 14,013 shares Expires 2030-05-28 F1 · derivative.exercise_date: This option will vest in full on May 29, 2021, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 16:03 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 5,625 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001457612-19-000109 · wf-form4_156356660832230.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2029-07-18 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:58 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $100.45 | $0.00 |
DisclosureSEC source: 0000899243-19-018673 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 17:01 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0000899243-19-016837 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from July 1, 2019 through June 1, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 16:05 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $6.53 | $0.00 |
DisclosureSEC source: 0001179110-19-007182 · edgar.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-03 F1 · derivative.exercise_date: This option was granted on June 4, 2019 and is scheduled to vest in full on June 4, 2020. Read SEC document |
| May 31, 2019 Filed Jun 7, 2019 16:28 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 17,633 | $0.00 Strike: $13.74 | $0.00 |
DisclosureSEC source: 0000899243-19-016017 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,633 Underlying: Common Stock · 17,633 shares Expires 2029-05-30 F1 · derivative.exercise_date: This option will vest in full on May 31, 2020, subject to Reporting Person's continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:07 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001457612-18-000069 · wf-form4_152997166026024.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 19, 2018 Filed Jun 22, 2018 00:52 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $303.79 | $0.00 |
DisclosureSEC source: 0001179110-18-008929 · edgar.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 16:31 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0000899243-18-017175 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-17 F1 · derivative.exercise_date: This option vests in equal monthly installments from July 1, 2018 through June 1, 2019 subject to the Reporting Person's continued service to the company. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 18:05 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001179110-18-008242 · edgar.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option was granted on June 7, 2018 and is scheduled to vest in full on June 7, 2019. Read SEC document |
| May 18, 2018 Filed May 31, 2018 16:25 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034364 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-17 F1 · derivative.exercise_date: This option was granted on May 18, 2018, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on May 18, 2019 and, in the event of a change in control of the Company, the vesting will accelerate in full. Read SEC document |
| July 27, 2017 Filed Jul 28, 2017 16:05 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001179110-17-010772 · edgar.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2027-07-26 F1 · derivative.exercise_date: This option was granted on July 27, 2017 and is scheduled to vest in full on June 7, 2018. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 21:59 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001179110-17-009842 · edgar.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the date of grant, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 16:00 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0001209191-17-041823 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option was granted on June 22, 2017, pursuant to the Company's 2013 Stock Incentive Plan with respect to 12,500 shares of Common Stock and vests in full on June 22, 2018 and, in the event of a change in control of the Company, the vesting will accelerate in full. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 17:01 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 57,857 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000899243-17-017107 · doc4.xml · derivative · entry 2 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,857 Underlying: Common Stock · 57,857 shares Expires 2027-06-21 F2 · derivative.exercise_date: This option vests in equal quarterly installments from June 1, 2017 through June 1, 2018 subject to the Reporting Person's continued service to the company. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 17:01 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000899243-17-017107 · doc4.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option vests in equal monthly installments from June 1, 2017 through June 1, 2018 subject to the Reporting Person's continued service to the company. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0001104659-17-040261 · a4.xml · derivative · entry 2 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 21:58 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-040261 · a4.xml · nonDerivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 15, 2018, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 16:57 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $5.34 Strike: $5.34 | $80,100.00 |
DisclosureSEC source: 0001210238-17-000003 · wf-form4_149756023558197.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| July 22, 2016 Filed Oct 24, 2016 23:09 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001179110-16-030885 · edgar.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-07-22 F1 · derivative.exercise_date: Fifty percent (50%) of the option vests on July 22, 2017 and thereafter it vests at a rate of twelve and one-half percent (12.5%) per quarter for four (4) successive quarters. The filing is late due to an administrative oversight. Read SEC document |
| July 22, 2016 Filed Nov 4, 2016 21:16 UTC Amendment | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001179110-16-031249 · edgar.xml · derivative · entry 1 BATE KENNETH · CIK 0001210238 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-07-22 F1 · derivative.exercise_price: This report amends the original report to reflect the correct exercise price of $9.45 per share. F2 · derivative.exercise_date: Fifty percent (50%) of the option vests on July 22, 2017 and thereafter it vests at a rate of twelve and one-half percent (12.5%) per quarter for four (4) successive quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.